PriceTargets.com logo

OTCMKTS:ESALY - Eisai Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$42.97 As of 07/5/2022 01:00 AM ET
▲ +0.39 (0.92%)

This chart shows the closing price for ESALY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eisai Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESALY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESALY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Eisai in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $42.97.

This chart shows the closing price for ESALY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Eisai. This rating has held steady since January 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/13/2022CitigroupDowngradeBuy ➝ Neutral
6/25/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
6/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/5/2020Jefferies Financial GroupUpgradeHold ➝ Buy
9/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
9/24/2019Jefferies Financial GroupInitiated CoverageBuy
9/17/2019Daiwa Capital MarketsDowngradeNeutral ➝ Sell
8/5/2019CitigroupUpgradeSell ➝ Neutral
3/25/2019UBS GroupReiterated RatingNeutral ➝ Sell
3/22/2019Nomura SecuritiesReiterated RatingBuy ➝ Reduce
3/22/2019CitigroupDowngradeNeutral ➝ Sell
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/7/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Eisai logo
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $42.97
Low: $42.33
High: $42.97

50 Day Range

MA: $41.51
Low: $37.90
High: $44.16

52 Week Range

Now: $42.97
Low: $36.88
High: $98.27

Volume

13,059 shs

Average Volume

28,829 shs

Market Capitalization

$12.32 billion

P/E Ratio

27.83

Dividend Yield

2.49%

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Eisai?

The following equities research analysts have issued stock ratings on Eisai in the last year: Citigroup Inc..
View the latest analyst ratings for ESALY.

What is the current price target for Eisai?

0 Wall Street analysts have set twelve-month price targets for Eisai in the last year.
View the latest price targets for ESALY.

What is the current consensus analyst rating for Eisai?

Eisai currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESALY, but not buy more shares or sell existing shares.
View the latest ratings for ESALY.

How do I contact Eisai's investor relations team?

Eisai's physical mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company's listed phone number is (133) 817-3700. The official website for Eisai is www.eisai.co.jp. Learn More about contacing Eisai investor relations.